Fusion Pharmaceuticals (FUSN) Appoints Jeremy Bender, Teresa Bitetti and David Meek to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
HAMILTON, ON and BOSTON, Oct. 16, 2023 /PRNewswire/ Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision.
Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Published: May 13, 2021
Bob Linke appointed Chief Executive Officer
NEW HAVEN, Conn. (BUSINESS WIRE) Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022. There are currently no Food and Drug Administration (FDA) approved therapies for the prevention or treatment of CIPN, a debilitating condition resulting from the off-target toxicity of many chemotherapy treatments.
Osmol was founded by Dr. Barbara Ehrlich, Professor of Pharmacology and of Cellular and Molecular Physiology, Yale School of Medicine. Her research on neuronal calcium sensor-1 (NCS1), a critical calcium binding protein that regulates intracellular calcium levels, forms the basis of Osmol’s CIPN treatment, OSM-0205 and future potential NCS1 therapeutics. OSM-0205’s mechanism addresses the off-target toxicity of